cagrilintide trial ECO 2026 Cagrilintide–semaglutide (CagriSema) versus semaglutide or

Non sono state osservate evidenze di effetti avversi ormonali, epatici o sistemici nei dati disponibili

This study demonstrated that PSSI 90 and PSSI 100 results were maintained until week 60 in patients initially treated with ixekizumab 2-week dosing who were switched to 4-week dosing schedules (79.1% and 75.9%) as well as patients continued on a ixekizumab 4-week dosing schedule (76.2% and 73.6%) [45]

Lyophilised (freeze-dried) peptides should be stored at 20C before reconstitution

Ethical considerations: equity of access to life-extension therapies, off-label usage, anti-ageing claims and regulatory scrutiny